A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs LY 3300054 (Primary) ; LY 3381916 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 12 Sep 2018 Planned End Date changed from 1 Dec 2020 to 7 Dec 2020.
- 12 Sep 2018 Planned primary completion date changed from 1 Sep 2019 to 14 Sep 2019.
- 30 Nov 2017 Status changed from not yet recruiting to recruiting.